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I. Dugue´pe´roux1,2, M.-P. Audre´zet1,2, P. Parent3, C. Fe´rec1,2, V. Scotet1. 1INSERM
U. 1078, Brest, France; 2University Hospital, Dep. of Molecular Genetics, Brest,
France; 3University Hospital, Dep. of Medical Genetics, Brest, France
DNA-based newborn screening (NBS) for CF leads to the unwanted but inevitable
detection of some carrier newborns. Knowledge of this status nevertheless provides
opportunity for the parents and relatives to beneﬁt from cascade carrier testing.
We report a unique assessment of the use of cascade testing in families of carriers
identiﬁed by NBS in an area where CF is frequent (western Brittany, France) and
where NBS is under way for over 20 years.
We reviewed all the carriers identiﬁed by NBS in the district of Finiste`re since use
of IRT/DNA protocol (1991–2010). We recorded the carrier tests made in those
families in the sole genetic laboratory of our area.
Among the 200,378 newborns screened over that period, 199 (0.1%), from 195
families, were identiﬁed as CF carriers. Considering the incidence observed over
that time (1/2569) and the deducted carrier rate (1/26), we estimated that NBS
detected only 2.6% of all the expected carriers born over that period.
To date, 148 (75.9%) of the families have used carrier testing and 389 tests were
done (mean number/family: 2.6; range: [1−9]). Cascade testing was mainly used
by the parents (74.6% of the tests; 97.9% of the parents tested) and uncles/aunts
(14.4%). Overall, cascade testing identiﬁed 185 CF carriers and detected 5 new
1-in-4 risk couples (3 parent and 2 uncle/aunt couples). Of them 4 requested prenatal
diagnosis 5 times for subsequent pregnancies. One affected pregnancy was detected
and terminated.
Carriers detected by NBS appeared to be well managed in our area and cascade
testing, that prevents birth of CF children, seems relatively active.
Approved by our local ethical committee.
WS21.10 The impact of a national newborn screening programme on
sweat testing services
J. Harrington1, K.W. Southern1, P. Barton2, E. Hanmer2, E. Burrows3. 1University
of Liverpool, Liverpool, United Kingdom; 2Department of Biochemistry, Alder
Hey Children’s Hospital, Liverpool, United Kingdom; 3Regional Paediatric Cystic
Fibrosis Unit, Alder Hey Children’s Hospital, Liverpool, United Kingdom
Objectives: Newborn screening (NBS) for CF was implemented in the Cheshire
and Merseyside region of the UK in February 2007. Sweat testing is an integral
component of the UK NBS protocol. We were concerned about the long-term impact
of the NBS programme on referral rates for sweat testing. The objective of this
research was to identify patterns in sweat testing numbers since NBS commenced,
and assess whether laboratories are within national targets of performing a minimum
of 50 sweat tests per year.
Methods: The number of sweat tests performed annually from 2005 until the end of
June 2011 was provided by 9 sweat testing laboratories in Cheshire and Merseyside.
Conclusions: Sweat testing has decreased since NBS. After a peak in 2007 with
765 regional sweat tests performed, sweat testing has declined with 611 sweat tests
performed in 2010 and an estimated 502 tests performed in 2011. 6/9 laborato-
ries did not meet the minimum annual number of sweat tests recommended by
UK guidelines. We anticipated an initial increase in sweat testing following the
implementation of NBS. The data supports that, but shows a subsequent signiﬁcant
reduction in sweat testing 5 years after the implementation of NBS. Reasons for
this reﬂect an increasing awareness among paediatricians of NBS and possibly a
false reassurance that children will not have a CF diagnosis following screening.
Education is vital that the threshold for sweat testing must remain low in children
with suggestive clinical features. The reduction in sweat testing has implications for
the sustainability of the service: changes to the service may need to be considered
such as centralisation or an ambulatory service.
